ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Anticoagulant therapy for acute venous thromboembolism [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2017; 45(6): 563-571 | DOI: 10.5543/tkda.2017.94838

Anticoagulant therapy for acute venous thromboembolism

Hilal Ermiş1, Necip Ermiş2
1Department of Pulmonary Medicine, İnönü University Faculty of Medicine, Malatya, Turkey
2Department of Cardiology, İnönü University Faculty of Medicine, Malatya, Turkey

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are currently defined as venous thromboembolism (VTE) since they share pathophysiological features and the treatment is similar in many respects. It has been determined that more than 90% of PE cases originate from DVT in the legs. PE, which is difficult to diagnose, has a mortality rate of 12% when untreated. The worldwide increase in obesity, cancer diseases, and average survival time also contribute to the increase in the incidence of VTE. Traditional treatment of VTE includes heparin, low-molecular-weight heparin, and warfarin. Despite availability for oral use, warfarin has a narrow therapeutic range and a wide range of food interactions. After many years of research, new oral anticoagulant agents (NOACs) are expected to overcome these handicaps in treatment. In this review, the use of NOACs in the treatment of VTE is investigated in the light of current guidelines.

Keywords: Anticoagulant treatment, deep venous thrombosis, pulmonary embolism.

How to cite this article
Hilal Ermiş, Necip Ermiş. Anticoagulant therapy for acute venous thromboembolism. Turk Kardiyol Dern Ars. 2017; 45(6): 563-571

Corresponding Author: Necip Ermiş, Türkiye
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.